Cantor Fitzgerald
Entity.
- Evidence
- 54 documents · 25 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 3 Sept 2026, last seen 7 Oct 2026
- Measured
- 13% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- Blockchain News · 2026-10-07 · TSLA Price Prediction: Q3 Earnings on Oct 20 Are the Make-or-Break Moment — $400 or $350? (opens the source in a new tab)
- Blockchain News · 2026-10-07 · NVDA Price Prediction: Momentum Is Stalling at $239 — The Flush Before $300 Is the Trade (opens the source in a new tab)
- New York Post · 2026-10-07 · Families of 9/11 victims to pack NYC court as Saudi gov’t tries to dodge civil trial: ‘The Kingdom continues to lie’ (opens the source in a new tab)
- The Guardian · 2026-10-06 · UK regulator FCA to investigate how it handled Epstein whistleblower who took his own life (opens the source in a new tab)
- Blockchain News · 2026-10-06 · NVDA Price Prediction: Overbought at $240.90 — Shakeout First, Then $260+ (opens the source in a new tab)
- Blockchain News · 2026-10-05 · NVDA Price Prediction: Pre-Earnings Drift Sets Up Bull Case to $270 — But $237 Must Break First (opens the source in a new tab)
- Electrek · 2026-10-04 · Tesla (TSLA) Q3 2026 deliveries slip 2% to 486,532, but beat estimates (opens the source in a new tab)
- Blockchain News · 2026-10-04 · MSFT Price Prediction: Azure's AI Revenue Machine Eyes $575 as $519 Resistance Looms (opens the source in a new tab)
- MarketBeat News Feed · 2026-10-04 · Arcturus Therapeutics (NASDAQ:ARCT) Cut to "Sell" at Wall Street Zen (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-28 · Ascendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Cantor Fitzgerald (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-22 · Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-18 · Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock (opens the source in a new tab)